Université Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.
INSERM UMR_S 999, HPPIT, Le Kremlin-Bicêtre, France.
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01095-2024. Print 2024 Oct.
In recent years, major advances have been made in the understanding of the cellular and molecular mechanisms driving pulmonary vascular remodelling in various forms of pulmonary hypertension, including pulmonary arterial hypertension, pulmonary hypertension associated with left heart disease, pulmonary hypertension associated with chronic lung disease and hypoxia, and chronic thromboembolic pulmonary hypertension. However, the survival rates for these different forms of pulmonary hypertension remain unsatisfactory, underscoring the crucial need to more effectively translate innovative scientific knowledge into healthcare interventions. In these proceedings of the 7th World Symposium on Pulmonary Hypertension, we delve into recent developments in the field of pathology and pathophysiology, prioritising them while questioning their relevance to different subsets of pulmonary hypertension. In addition, we explore how the latest omics and other technological advances can help us better and more rapidly understand the myriad basic mechanisms contributing to the initiation and progression of pulmonary vascular remodelling. Finally, we discuss strategies aimed at improving patient care, optimising drug development, and providing essential support to advance research in this field.
近年来，人们对各种形式的肺动脉高压（包括肺动脉高压、与左心疾病相关的肺动脉高压、与慢性肺部疾病和缺氧相关的肺动脉高压以及慢性血栓栓塞性肺动脉高压）中驱动肺血管重构的细胞和分子机制有了更深入的了解。然而，这些不同形式的肺动脉高压的存活率仍不尽人意，这突显了将创新科学知识更有效地转化为医疗干预措施的迫切需要。在第七届世界肺动脉高压研讨会上，我们深入探讨了病理学和病理生理学领域的最新进展，并对其进行了优先排序，同时质疑它们与不同亚组肺动脉高压的相关性。此外，我们还探讨了最新的组学和其他技术进步如何帮助我们更好、更快地理解导致肺血管重构发生和发展的众多基本机制。最后，我们讨论了旨在改善患者护理、优化药物开发以及为推进该领域研究提供必要支持的策略。
